Logo image
Update on intra-arterial chemotherapy for retinoblastoma
Journal article   Open access

Update on intra-arterial chemotherapy for retinoblastoma

Mario Zanaty, Guilherme Barros, Nohra Chalouhi, Robert M Starke, Philip Manasseh, Stavropoula I Tjoumakaris, Carol L Shields, David Hasan, Ketan Bulsara, Robert H Rosenwasser, …
TheScientificWorld, Vol.2014, pp.869604-6
2014
DOI: 10.1155/2014/869604
PMCID: PMC4227378
PMID: 25405236
url
https://doi.org/10.1155/2014/869604View
Published (Version of record) Open Access

Abstract

The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy (IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications, complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies.
Infusions, Intra-Arterial - methods Retinoblastoma - economics Eye Enucleation - economics Humans Retinoblastoma - drug therapy Retinal Neoplasms - pathology Salvage Therapy Treatment Outcome Antineoplastic Agents - therapeutic use Melphalan - therapeutic use Retinoblastoma - pathology Retinal Neoplasms - drug therapy Retinal Neoplasms - economics Ophthalmic Artery Retinal Neoplasms - surgery Eye Enucleation - methods Child Retinoblastoma - surgery

Details

Metrics

37 Record Views
Logo image